LA JOLLA, Calif. — Topcon Healthcare, Inc. has acquired RetInSight GmbH to boost AI imaging in eye care. The move advances Topcon’s vision of Healthcare from the Eye. The goal is to improve access to intelligent diagnostics. This will enhance eye care quality, lower costs and improve outcomes.
RetInSight’s AI analyzes OCT images from routine care. It detects and monitors major retinal diseases that cause global vision loss. These tools enable earlier intervention and personalized treatment planning, especially for aging populations.
“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally,” said Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight. “This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide.”
RetInSight’s platform, born from pioneering research at the Medical University of Vienna, Department of Ophthalmology and Optometry, under the direction of Prof. Dr. Ursula Schmidt-Erfurth, is already commercialized throughout Europe and is vendor-inclusive supporting interoperability across multiple OCT systems.
“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “Integrated with our Harmony vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”
Already used in pharmaceutical trials, RetInSight’s algorithms also support AI-powered drug development and regulatory pathways, including advancing FDA clearances for U.S. indications.
“Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”
Author
